OncoC4 Receives FDA Fast Track Designation for Cesalatamig, an Investigational PD-1/VEGF Bispecific Antibody
Cesalatamig is Currently Being Evaluated in Phase 1/2 Studies in the United States ( NCT06635785 ) and in China ( CTR20253261 ) Fast Track Designation Supports Expedited Development of Cesalatamig for Non-small Cell Lung Cancer (NSCLC) that...